NDAORALCAPSULE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRINCIPEN '500' is an oral ampicillin capsule (500 mg), a broad-spectrum beta-lactam antibiotic used to treat bacterial infections across multiple body systems. Ampicillin works by inhibiting bacterial cell wall synthesis, making it bactericidal. This product targets patients requiring oral antibiotic therapy for susceptible gram-positive and gram-negative infections.
Pre-Launch
Pre-launch status signals opportunity for launch-focused roles in commercial, medical affairs, and market access teams at Bristol Myers Squibb.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRINCIPEN '500' offers opportunity to execute a launch strategy in a mature, competitive antibiotic market where commercial execution, pricing strategy, and provider relationships drive success. Roles focus on launch readiness, distribution partnerships, and market penetration rather than clinical innovation or patent defense.
Brand ManagerCommercial Launch Lead
Worked on PRINCIPEN '500' at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.